ADMA Biologics to Report Third Quarter 2023 Financial Results on November 8, 2023

Rhea-AI Summary

ADMA Biologics, Inc. will report its third quarter 2023 financial results on November 8, 2023, after the U.S. financial markets close. The management team will host a live conference call and webcast to discuss the financial results and other updates. Participants can register for the call to receive the dial-in numbers and unique PIN. The webcast will be available on the Company's website.

Conference Call Scheduled for November 8, 2023, at 4:30 p.m. ET

RAMSEY, N.J. and BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced that it will report third quarter 2023 financial results on November 8, 2023, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.

To access the conference call seamlessly, participants may register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join 10 minutes prior to the event start (although you may register and dial in at any time during the call). A live audio webcast of the call will be available under “Events & Webcasts” in the investor section of the Company’s website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company’s website approximately two hours after the event.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM^® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB^® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 and European Patent No. 3375789, among others, related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

COMPANY CONTACT:
Skyler Bloom
Senior Director, Business Development & Corporate Strategy | 201-478-5552 | sbloom@admabio.com

INVESTOR RELATIONS CONTACT:
Jason Finkelstein
Managing Director, Argot Partners | 212-600-1902 | jason@argotpartners.com

FAQ

When will ADMA Biologics, Inc. report its third quarter 2023 financial results?

ADMA Biologics, Inc. will report its third quarter 2023 financial results on November 8, 2023, after the U.S. financial markets close.

What will be discussed during the conference call and webcast?

The management team will discuss ADMA Biologics, Inc.'s financial results for the third quarter of 2023 and provide other Company updates.

How can participants access the conference call?

Participants can register for the call to receive the dial-in numbers and unique PIN. It is recommended to join 10 minutes prior to the event start.

Where can the webcast be accessed?

The webcast will be available under 'Events & Webcasts' in the investor section of ADMA Biologics, Inc.'s website.

Will the webcast be available after the event?

Yes, an archived webcast will be available on ADMA Biologics, Inc.'s website approximately two hours after the event.